Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 21, 2017

Primary Completion Date

June 1, 2019

Study Completion Date

June 1, 2020

Conditions
Relapsed or Refractory B-cell Lymphoma
Interventions
BIOLOGICAL

iPD1 CD19 eCAR T cells

"iPD1 CD19 eCAR T cells are administrated in a 3-day split-dose regimen (d0, 30%; d1, 30%; d2, 40%).~CAR T cell dose escalation: 1×10\^5 /kg,1×10\^6 /kg,3×10\^6 /kg,and 6×10\^6 CAR T cells/kg"

DRUG

Fludarabine and cyclophosphamide

Fludarabine 25 mg/m2 d1-3; cyclophosphamide 250 mg/m2 d1-3. Lymphodepletion chemotherapy is completed 1 to 4 days before CAR T cell infusion

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hosptical, Beijing

Sponsors
All Listed Sponsors
collaborator

Marino Biotechnology Co., Ltd.

INDUSTRY

lead

Peking University

OTHER